Omeros (NASDAQ:OMER) Stock Rating Upgraded by Wall Street Zen

Omeros (NASDAQ:OMER) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other equities research analysts have also recently issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, August 15th. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Omeros Price Performance

Shares of Omeros stock opened at $4.18 on Friday. The business has a fifty day simple moving average of $4.04 and a two-hundred day simple moving average of $5.00. Omeros has a 1 year low of $2.95 and a 1 year high of $13.60. The company has a market capitalization of $284.49 million, a price-to-earnings ratio of -1.98 and a beta of 2.37.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million for the quarter, compared to analyst estimates of $0.31 million. As a group, equities analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Omeros during the first quarter worth $579,000. GAMMA Investing LLC increased its holdings in shares of Omeros by 14,486.3% during the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 7,388 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Omeros during the first quarter worth $142,000. Deutsche Bank AG increased its holdings in shares of Omeros by 38.2% during the fourth quarter. Deutsche Bank AG now owns 40,046 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 11,068 shares in the last quarter. Finally, Sowell Financial Services LLC acquired a new position in shares of Omeros during the first quarter worth $88,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.